<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600405</url>
  </required_header>
  <id_info>
    <org_study_id>2958</org_study_id>
    <nct_id>NCT00600405</nct_id>
  </id_info>
  <brief_title>The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients</brief_title>
  <official_title>The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maine Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maine Medical Center Mentored Research Committee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maine Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of the Î±-adrenergic antagonist
      tamsulosin in the treatment of adult emergency department (ED) patients with ureteral colic
      secondary to lower ureteral calculus. We hypothesize that there will be no difference in
      outcomes for subjects treated with and without tamsulosin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, randomized controlled trial seeks to compare outcomes for adult emergency
      department patients with lower ureteral calculus. Subjects will be randomized to receive
      treatment with ibuprofen and oxycodone alone (standard therapy) or standard therapy plus
      tamsulosin 0.4mg orally once daily for ten days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of spontaneous ureteral stone expulsion</measure>
    <time_frame>48, 120, 336 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to spontaneous ureteral stone expulsion.</measure>
    <time_frame>48, 120, 336 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported NRS-11 pain scores.</measure>
    <time_frame>48, 120, 336 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of colicky pain episodes.</measure>
    <time_frame>48, 120, 336 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days missed work or usual functional ability.</measure>
    <time_frame>48, 120, 336 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of return ED visits or unscheduled PCP visits for continued pain.</measure>
    <time_frame>48, 120, 336 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of narcotic pain medication used.</measure>
    <time_frame>48, 120, 336 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse medication-related events.</measure>
    <time_frame>48, 120, 336 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Nephrolithiasis</condition>
  <condition>Ureteral Calculi</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the experimental group receive ibuprofen, oxycodone, and tamsulosin 0.4 mg orally daily for ten days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard therapy arm: subjects randomized to standard therapy receive ibuprofen and oxycodone alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamsulosin</intervention_name>
    <description>Tamsulosin 0.4 mg orally daily for ten days.</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Flomax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard therapy with ibuprofen and oxycodone.</intervention_name>
    <description>Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.</description>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older;

          -  able to read, write, and speak English;

          -  able to use the NRS pain scale; and

          -  computed tomography diagnosed single lower ureteral calculus

        Exclusion Criteria:

          -  allergy or sensitivity to the study drug (tamsulosin hydrochloride [Flomax]);

          -  sulfa/sulfonamide allergy;

          -  inability to provide informed consent;

          -  lithiasis of the ureteral intramural tract;

          -  acute or chronic renal failure;

          -  fever;

          -  presence of multiple ureteral stones;

          -  peptic ulcer disease;

          -  liver failure;

          -  concomitant treatment with alpha-lytic drugs, calcium antagonists, nitrates, or
             vardenafil (Levitra);

          -  pregnancy;

          -  breastfeeding; or

          -  a history of urinary surgery or endoscopic treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew D Perron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maine Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <last_update_submitted>January 14, 2008</last_update_submitted>
  <last_update_submitted_qc>January 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Andrew Perron, MD</name_title>
    <organization>Maine Medical Center</organization>
  </responsible_party>
  <keyword>Nephrolithiasis</keyword>
  <keyword>Ureteral Calculi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

